Abstract
A randomized, non-comparative, phase II multicentric trial on short-term darolutamide (ODM-201) concomitant to radiation therapy for patients with unfavorable intermediate-risk prostate cancer: DARIUS (AFU-GETUG P15).
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have